{"entity":{"id":"nct07705919","kind":"trial","name":"DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer","aka":[],"tldr":"A phase 1/2 trial of fluorouracil (5-FU), gemcitabine, fOLFIRI (5-FU, leucovorin, irinotecan), leucovorin (folinic acid) and other drugs in pancreatic cancer, run by Ohio State University Comprehensive Cancer Center, not yet recruiting.","summary":"DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer is a phase 1/2, interventional study registered as NCT07705919 by Ohio State University Comprehensive Cancer Center, with a registry enrolment figure of 50 participants, started 2026-09-01 and due to reach its primary completion in 2027-12-31. Interventions recorded: Biospecimen Collection; Computed Tomography; Dynamic Contrast-Enhanced Magnetic Resonance Imaging; Fluorouracil; Gadolinium-Chelate; Gemcitabine; Irinotecan; Leucovorin Calcium; Nab-paclitaxel; Oxaliplatin; Point-of-care portable perfusion phantom (P4). Conditions listed: Borderline Resectable Pancreatic Ductal Adenocarcinoma. Primary outcome: R0 resection rate. Pancreatic eligibility wording from the registry: \"* Histological or cytological evidence of pancreatic adenocarcinoma\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07705919","url":"https://clinicaltrials.gov/study/NCT07705919"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["borderline-resectable-pdac","resectable-pdac"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["fluorouracil","gemcitabine","folfiri","leucovorin","nab-paclitaxel","capox"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07705919","phase":"1/2","setting":"DCE-MRI-Informed Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer","sponsor":"Ohio State University Comprehensive Cancer Center","enrolled":50,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07705919/","neighbours":{"cancer":[{"id":"borderline-resectable-pdac","kind":"cancer","name":"Borderline resectable pancreatic ductal adenocarcinoma","route":"/cancers/borderline-resectable-pdac/"},{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/"},{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/"},{"id":"folfiri","kind":"drug","name":"FOLFIRI (5-FU, leucovorin, irinotecan)","route":"/drugs/folfiri/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"leucovorin","kind":"drug","name":"Leucovorin (folinic acid)","route":"/drugs/leucovorin/"},{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}